Document:

<PAGE>

                                                                   EXHIBIT 10.29

                             PATENT OPTION AGREEMENT

               Offer of this agreement is open until June 8, 2001

  This Agreement is made as of the date set forth above the signatures of the
parties below (the "EFFECTIVE DATE"), by and between the Massachusetts Institute
of Technology, a Massachusetts corporation having its principal office at 77
Massachusetts Avenue, Cambridge, Massachusetts 02139 ("M.I.T.") and Cerebrotec,
Inc., a corporation having its principal office at 308A Hunnewell St., Needham,
Massachusetts 02494 ("COMPANY").

         WHEREAS, M.I.T. is the owner of certain PATENT RIGHTS (as later defined
herein) relating to M.I.T. Case No. [*] and has the right to grant licenses
under said PATENT RIGHTS, subject only to a royalty-free, nonexclusive
nontransferable license to practice the PATENT RIGHTS reserved by the United
States Government;

         WHEREAS, M.I.T. desires to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant a license
thereunder; and

         WHEREAS, COMPANY desires a period of time in which to internally
evaluate the PATENT RIGHTS, potential products and markets therefor, and in
which to elect to negotiate a license.

         NOW, THEREFORE, in consideration of the promises and mutual covenants
contained herein, the parties hereto agree as follows:

         1.       Definition of PATENT RIGHTS. "PATENT RIGHTS" means the United
                  States and foreign patents, patent applications, and
                  provisional applications set forth on Appendix A.

         2.       Grant of Option Right. M.I.T. hereby grants COMPANY an option
                  to negotiate a worldwide, royalty-bearing, limited-term
                  exclusive license under the PATENT RIGHTS in the following
                  field: Stroke recovery (the "Option Right"). COMPANY may
                  exercise the Option Right upon written notice to M.I.T.
                  received by M.I.T. within six months after the EFFECTIVE DATE
                  (the "Option Period"). If COMPANY does not elect to exercise
                  the Option Right, or fails to exercise the Option Right during
                  the Option Period, M.I.T. shall be free to license its rights
                  under the relevant PATENT RIGHTS to any third party and this
                  Agreement shall terminate. If COMPANY does elect to exercise
                  the Option Right, M.I.T. and COMPANY shall negotiate in good
                  faith a license agreement containing commercially reasonable
                  terms and conditions. If M.I.T. and COMPANY are unable to
                  reach agreement within ninety (90) days after COMPANY has
                  exercised the Option Right, this Agreement shall terminate.
                  Thereafter, M.I.T. may offer its rights in the PATENT RIGHTS
                  to any third parties.

         3.       Limited License. M.I.T. hereby grants COMPANY an internal use
                  license during the Option Period to practice the PATENT RIGHTS
                  solely for the purpose of

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                  COMPANY's internal evaluation of the PATENT RIGHTS in
                  furtherance of this Agreement. During the Option Period,
                  COMPANY shall use commercially reasonable efforts to evaluate
                  the PATENT RIGHTS with a view toward creating a commercial
                  product or process that will be covered by the PATENT RIGHTS.

                           In addition, M.I.T. hereby grants COMPANY an internal
                  use license during the Option Period to use, solely for the
                  purpose of COMPANY's internal evaluation, the materials
                  described and given to COMPANY under the terms of the Material
                  Transfer Agreement ("TANGIBLE PROPERTY") attached herein as
                  Appendix B.

         4.       Option Fee. In consideration of the rights granted COMPANY
                  under this Agreement, COMPANY shall pay to M.I.T. a
                  nonrefundable option fee of Five Thousand Dollars ($5,000) on
                  the EFFECTIVE DATE.

         5.       Payment of Patent Expenses. Within thirty (30) days after
                  M.I.T. invoices COMPANY, COMPANY shall reimburse M.I.T. for
                  all patent-related expenses (including attorneys' fees)
                  incurred by M.I.T. during the term of this Agreement in
                  connection with obtaining or maintaining the PATENT RIGHTS.

                           During the Option Period, M.I.T. will notify COMPANY
                  in writing of any pending action on the U.S. patent
                  applications corresponding to the PATENT RIGHTS that may
                  result in such patent-related expenses exceeding Five Thousand
                  Dollars ($5,000). Should COMPANY refuse to pay for such
                  action, and if such action is necessary to retain U.S. patent
                  rights, this agreement will terminate immediately.

                           During the Option Period, COMPANY may elect to have
                  M.I.T. file foreign patent applications corresponding to the
                  PATENT RIGHTS in such countries as COMPANY may select by
                  written notice on or before May 31, 2001, and such foreign
                  filings shall be added to Appendix A and shall be included in
                  the definition of PATENT RIGHTS. COMPANY shall reimburse
                  M.I.T. for all patent-related expenses (including attorneys'
                  fees) incurred by M.I.T. during the term of this Agreement in
                  connection with obtaining or maintaining such foreign PATENT
                  RIGHTS.

         6.       Extension of Option Period. COMPANY shall have the right to
                  extend the Option Period for an additional six (6) month
                  period by giving M.I.T. written notice of such extension one
                  month prior to the expiration of the Option Period. If COMPANY
                  elects to extend the Option Period, then an option fee of Five
                  Thousand Dollars ($5,000) shall be due and payable to M.I.T.
                  at the time written notice of such extension is provided to
                  M.I.T.

         7.       Survival. Sections 4, 5, 6 (to the extent payments are due),
                  7, and 9 shall survive the expiration or termination of this
                  Agreement.

                                       2
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
         8.       Termination for Default. In the event COMPANY commits a
                  material breach of its obligations under this Agreement and
                  fails to cure that breach within thirty (30) days after
                  receiving written notice thereof, M.I.T. may terminate this
                  Agreement immediately upon written notice to COMPANY.

         9.       Termination by COMPANY. COMPANY shall have the right to
                  terminate this Agreement, for any reason upon at least sixty
                  (60) days prior written notice to M.I.T., such notice to state
                  the date at least sixty (60) days in the future upon which
                  termination is to be effective, and (ii) upon payment of all
                  amounts due to M.I.T. through such termination effective date.
                  COMPANY shall not be responsible for patent-related expenses
                  (including attorneys' fees) incurred by M.I.T. in connection
                  with obtaining or maintaining PATENT RIGHTS after such
                  terminate date.

         10.      Miscellaneous.

         (a)      Representations, Warranties and Damages Disclaimers. EXCEPT AS
                  EXPRESSLY STATED HEREIN, M.I.T. MAKES NO REPRESENTATIONS OR
                  WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS AND
                  TANGIBLE PROPERTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT
                  LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
                  PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS
                  CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT
                  OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTWITHSTANDING
                  THE FOREGOING, M.I.T. HEREBY REPRESENTS TO THE COMPANY THAT IT
                  HAS THE FULL RIGHT POWER, CAPACITY AND AUTHORITY TO LICENSE
                  AND DELIVER THE PATENT RIGHTS IN ACCORDANCE WITH THE TERMS OF
                  THIS AGREEMENT.

                           IN NO EVENT SHALL M.I.T., ITS TRUSTEES, DIRECTORS,
                  OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR
                  CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES
                  OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER
                  M.I.T. SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR
                  IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

         (b)      Assignment. This Agreement is personal to COMPANY and no
                  rights or obligations may be assigned by COMPANY, without the
                  prior written consent of M.I.T.; provided, however, COMPANY
                  may assign this Agreement, with written notice to M.I.T., in
                  connection with a merger, consolidation or sale of all or
                  substantially all of the assets of COMPANY, so long as the
                  assignee shall agree in writing to be bound by all the terms

                                       3
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                  and conditions hereof prior to such assignment. Failure of
                  such assignee to so agree shall be grounds for termination by
                  M.I.T.

         (c)      Governing Law. This Agreement, and any disputes arising in
                  connection herewith, shall be governed by and construed in
                  accordance with the laws of the Commonwealth of Massachusetts,
                  irrespective of any conflicts of law principles.

         (d)      Entire Agreement. This Agreement and the Material Transfer
                  Agreement constitute the entire agreement between the parties
                  with respect to the subject matter herein and supersedes all
                  prior agreements or understanding between the parties relating
                  to such subject matter.

         IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed under seal by their duly authorized representative.

         THE EFFECTIVE DATE OF THIS AGREEMENT IS MAY 21, 2001.

MASSACHUSETTS INSTITUTE OF                        CEREBROTEC, INC.
TECHNOLOGY

By: Signature of File                             By: /s/ Seth Finklestein
    ----------------------------------------          --------------------------

Name:                                             Name: Seth Finklestein
     ---------------------------------------            ------------------------

Title: Director Technology Licensing Office       Title: President
       ------------------------------------              -----------------------

                                       4
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX A

                              LIST OF PATENT RIGHTS

         M.I.T. Case No. [*]

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX B

                      MASSACHUSETTS INSTITUTE OF TECHNOLOGY

                                CEREBROTEC, INC.

                           MATERIAL TRANSFER AGREEMENT

The Massachusetts Institute of Technology (hereinafter "M.I.T.") and Dr. Ram
Sasisekharan (hereinafter "PROVIDER SCIENTIST") agree to provide Dr. Seth
Finklestein (hereinafter "RECIPIENT SCIENTIST") OF Cerebrotec, Inc. (hereinafter
"RECIPIENT") with material as described below subject to the terms and
conditions set forth in this Agreement.

                                 I. DEFINITIONS

1. ORIGINAL MATERIAL: shall be the [*]

2. MATERIAL; ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The
MATERIAL shall not include: (a) MODIFICATIONS, or (b) other substances created
by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS,
PROGENY, or UNMODIFIED DERIVATIVES.

3. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus,
cell from cell, or organism from organism.

4. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute
an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL.
Some examples include subclones of unmodified cell lines, purified or
fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA
supplied by M.I.T., or monoclonal antibodies secreted by a hybridoma cell line.

5. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate
the MATERIAL.

6. COMMERCIAL PURPOSES: Shall mean the sale, lease, license, or other transfer
of the MATERIAL or MODIFICATIONS. COMMERCIAL PURPOSES shall also include uses of
the MATERIAL or MODIFICATIONS by the organization, including RECIPIENT, to
perform contract research, to screen compound libraries, to produce or
manufacture products for general sale, or to conduct research activities that
result in any sale, lease, license, or transfer of the MATERIAL or
MODIFICATIONS.

                   II. TERMS AND CONDITIONS OF THIS AGREEMENT

1. M.I.T. retains ownership of the MATERIAL, including any MATERIAL contained or
incorporated in MODIFICATIONS.

2. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, M.I.T.
retains ownership rights to the MATERIAL (included therein), and (b) those
substances created

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY,
UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not contain the ORIGINAL
MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either 2(a) or 2(b) results from
the collaborative efforts of M.I.T. and the RECIPIENT, joint ownership may be
negotiated.

3. The RECIPIENT and the RECIPIENT SCIENTIST agree that the MATERIAL:

         (a)      is to be used solely for the purpose defined in Attachment A
                  (the "PURPOSE");

         (b)      will not be used in human subjects, in clinical trials, or for
                  diagnostic purposes involving human subjects;

         (c)      is to be used only at the RECIPIENT organization and only in
                  the RECIPIENT SCIENTIST's laboratory under the direction of
                  the RECIPIENT SCIENTIST or others working under his/her direct
                  supervision; and (d) will not be transferred to anyone else
                  within the RECIPIENT organization without the prior written
                  consent of M.I.T.

4. This Agreement is not assignable, whether by operation of law or otherwise,
other than in connection with a merger, consolidation, or sale of substantially
all of the assets of RECIPIENT. RECIPIENT may not transfer the MATERIAL to third
parties, except that MATERIAL may be transferred to a third party with which
RECIPIENT is MERGED, consolidated or sold.

5. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a
patent application. Except as provided in this Agreement, no express or implied
licenses or other rights are provided to the RECIPIENT under any patents, patent
applications, trade secrets or other proprietary rights of M.I.T., including any
altered forms of the MATERIAL made by M.I.T. In particular, no express or
implied licenses or other rights are provided to use the MATERIAL,
MODIFICATIONS, or any related patents of M.I.T. for COMMERCIAL PURPOSES.

6. If the RECIPIENT desires to use or license the MATERIAL or MODIFICATIONS for
COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate
in good faith with the PROVIDER to establish the terms of a commercial license.
It is understood by the RECIPIENT that the PROVIDER shall have no obligation to
grant such a license to the RECIPIENT, and may grant exclusive or non-exclusive
commercial licenses to others, or sell or assign all or part of the rights in
the MATERIAL to any third party(ies), subject to any pre-existing rights held by
others and obligations to the Federal Government.

7. The RECIPIENT is free to file patent application(s) claiming inventions made
by the RECIPIENT through the use of the MATERIAL but agrees to notify M.I.T.
upon filing a patent application claiming MODIFICATIONS or method(s) of
manufacture or use(s) of the MATERIAL.

8. Any MATERIAL delivered pursuant to this Agreement is understood to be
experimental in name and may have hazardous properties. M.I.T. MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

9. Except to the extent prohibited by law, the RECIPIENT assumes all liability
for damages which may arise from its use, storage or disposal of the MATERIAL.
M.I.T. will not be liable to the RECIPIENT for any loss, claim or demand made by
the RECIPIENT, or made against the RECIPIENT by any other party, due to or
arising from the use of the MATERIAL by the RECIPIENT, except to the extent
permitted by law when caused by the gross negligence or willful misconduct of
M.I.T.

10. This agreement shall not be interpreted to prevent or delay publication of
research findings resulting from the use of the MATERIAL or the MODIFICATIONS.
The RECIPIENT SCIENTIST agrees to provide appropriate acknowledgement of the
source of the MATERIAL in all publications.

11. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable
statutes and regulations, including Public Health Service and National Institute
of Health regulations and guidelines such as, for example, [illegible] relating
to research involving the use of animals or recombinant DNA.

12. This Agreement will terminate on the earliest of the following dates: (a)
when the MATERIAL becomes generally available from third parties, for example,
though reagent catalogs or public depositories or (b) the completion of the
PURPOSE with the MATERIAL, or (c) on thirty (30) days written notice by either
party to the other, or (d) upon the termination of the Option Agreement
effective May __, 2001, by and between the PROVIDER and RECIPIENT, provided
that:

         (a)      if termination should occur under 13(a), the RECIPIENT shall
                  be bound to the PROVIDER by the least restrictive terms
                  applicable to the MATERIAL obtained from the then-available
                  resources; and
         (b)      if termination should occur under 13(b), (c), or (d) above,
                  the RECIPIENT will discontinue its use of the MATERIAL and
                  will, upon direction of the PROVIDER, return or destroy any
                  remaining MATERIAL. The RECIPIENT, at its discretion, will
                  also either destroy the MODIFICATIONS or remain bound by the
                  terms of this agreement, as the apply to MODIFICATIONS.

13. Paragraphs 5, 8 and 9 shall survive termination.

If you agree to accept the MATERIAL under the above conditions, please have two
(2) original copies of this Agreement signed by an authorized representative of
RECIPIENT and RECIPIENT SCIENTIST and either PROVIDER SCIENTIST or an authorized
representative of M.I.T. and return one original to:

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                           Material Transfer Coordinator
                           Technology Licensing Office
                           Massachusetts Institute of Technology
                           77 Massachusetts Ave., Room NE25-230
                           Cambridge, MA 02139

The MATERIAL will be sent to you as soon as possible after receipt of the signed
Agreement.

MASSACHUSETTS INSTITUTE OF                      CEREBROTEC, INC.
TECHNOLOGY

By: Signature on File                           By: /s/ Seth Finklestein
    ----------------------------------------        ----------------------------

Name:                                           Name: Seth Finklestein
     ---------------------------------------          --------------------------

Title: Director Technology Licensing Office     Title: President
       ------------------------------------            -------------------------

Date: May 8, 2001                               Date: 5/23/01
      --------------------------------------          --------------------------

DR. RAM SASISEKHARAN                            DR. SETH FINKLESTEIN

By: /s/ Ram Sasisekharan                        By: /s/ Seth Finklestein
    ----------------------------------------        ----------------------------

Name: Ram Sasisekharan                          Name: Seth Finklestein
      --------------------------------------          --------------------------

Title: Assoc. Prof. MIT                         Title: President, Cerebrotec
       -------------------------------------           -------------------------

Date: May 24, 01                                Date: 5/23/01
      --------------------------------------          --------------------------

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                  ATTACHMENT A

                                   THE PURPOSE

Cerebrotec, Inc. plans to evaluate the MATERIAL in rat models of stroke recovery
as a potential therapeutic to reduce neurological disability following stroke.

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.<PAGE>

                                                                   Exhibit 10.31

                               RESEARCH AGREEMENT

         This Agreement is made as of the January 1, 2002 ("Effective Date"),
between ViaCell, Inc., a Delaware corporation having an address at One
Innovation Drive, Worcester MA 01605 ("VIACELL"), and The General Hospital
Corporation, a not-for-profit Massachusetts corporation doing business as
Massachusetts General Hospital, Fruit Street, Boston, Massachusetts 02114
("GENERAL").

         VIACELL desires GENERAL to perform research and evaluation herein
described upon the terms provided.

         NOW THEREFORE, the parties hereto agree as follows:

         1. The research project directed at ADMINISTRATION OF HUMAN UMBILICAL
CORD BLOOD CELLS IN AMYOTROPHIC LATERAL SCLEROSIS described in Appendix A and
funded by VIACELL ("Project") shall be performed by Dr. Robert Brown ("Principal
Investigator") and other GENERAL personnel working under the direction of
Principal Investigator (collectively with Principal Investigator,
"Investigators"). At the conclusion of the Project, a report disclosing the
results of the research shall be provided to VIACELL, which shall have the right
to use such results to the extent such use does not infringe any GENERAL patent
not expressly licensed to VIACELL herein.

         2. This Agreement shall remain in effect for a term of one (1) year
from the Effective Date.

         3. VIACELL agrees to provide GENERAL with a grant of [*] which includes
the full direct costs of the Project and the full indirect costs attendant
thereto, as shown in the Budget attached hereto as Appendix B. The foregoing
grant shall be paid on the following schedule:

                  [*]

Payment shall be made to "The General Hospital Corporation" and shall be sent
to:

         Financial Director, Grants and Contracts
         Research Finance
         Massachusetts General Hospital
         Fifty Staniford Street, 10th floor
         Boston, MA  02114

         4. In the event that either party discloses to the other party
information that relates to the Project which the disclosing party considers
confidential, the rights and obligations of the

                                       1
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
parties with respect to such information shall be governed by the terms and
conditions set forth in Appendix C.

         5.  ViaCell Proprietary Materials; Disclaimers.

Supply of ViaCell Proprietary Materials. For the purposes of this Agreement, the
term "ViaCell Proprietary Materials" shall mean any and all (i) materials
provided by VIACELL to GENERAL and Investigator hereunder, and (ii) materials
that incorporate or are combined with any materials provided by VIACELL to
GENERAL and Investigator hereunder. Promptly after the Effective Date, VIACELL
will provide to Investigator a reasonable quantity of the ViaCell Proprietary
Materials.

Ownership. VIACELL has developed the ViaCell Proprietary Materials over a
substantial period of time at substantial expense, and the ViaCell Proprietary
Materials are of great importance to VIACELL's business. Institution and
Investigator acknowledge that VIACELL is and will at all times remain the owner
of the ViaCell Proprietary Materials.

Limitations on Use and Transfer. Unless VIACELL has given prior written consent,
which shall not be unreasonably withheld, Institution and Investigator shall not
(a) use any ViaCell Proprietary Materials for any purposes other than performing
the Evaluation Plan during the Term, (b) use any ViaCell Proprietary Materials
in commercial research, which shall include but not be limited to research
sponsored by a third party commercial entity, (c) transfer or provide access to
the ViaCell Proprietary Materials to any third party, and/or (d) copy, reverse
engineer or attempt to derive the sequence or composition or underlying
information, structure or ideas of the ViaCell Proprietary Materials.

No Representations or Warranties: Compliance With Laws. Any ViaCell Proprietary
Materials delivered pursuant to this Agreement are understood to be experimental
in nature and may have hazardous properties. VIACELL MAKES NO REPRESENTATION OR
WARRANTY OF ANY KIND WITH RESPECT TO THE VIACELL PROPRIETARY MATERIALS OR
INFORMATION SUPPLIED BY IT TO INSTITUTION AND INVESTIGATOR HEREUNDER, AND
EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT
LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR
NON-INFRINGEMENT OF THIRD PARTY PATENTS, WITH RESPECT TO THE FOREGOING.
Institution will be solely responsible and liable, and shall indemnify and hold
harmless VIACELL, its directors, officers and employees, for any and all costs,
expenses (including attorneys' fees), damages and other liabilities arising from
activities undertaken by Institution and Investigator under this Agreement,
except to the extent (if any) resulting from the gross negligence or willful
misconduct of VIACELL. VIACELL will be solely responsible and liable, and shall
indemnify and hold harmless Institution, its directors, officers and employees,
for any and all costs, expenses (including attorneys' fees), damages and other
liabilities arising out of

                                       2
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
VIACELL's use of any Data generated under this Agreement, except to the extent
(if any) resulting from the gross negligence or willful misconduct of
Institution. Institution and Investigator will use all ViaCell Proprietary
Materials provided to it by VIACELL hereunder in compliance with all applicable
laws and regulations, including but not limited to those relating to animal
testing, biotechnological research or the handling and containment of
biohazardous materials. Institution and Investigator shall not use the ViaCell
Proprietary Materials in any in vivo experiments on human subjects.

No Implied License. Except for the right to use the ViaCell Proprietary
Materials to perform the Evaluation Plan, no license, express or implied, is
granted by VIACELL under any intellectual property rights owned or controlled or
developed hereunder by VIACELL.

         6. Investigators shall have the right to present or publish the results
of the Project and Principal Investigator shall provide an early draft of any
presentation or manuscript or abstract disclosing such results for review by
VIACELL prior to first public presentation or submission for publication, at
least thirty (30) days in advance in the case of a presentation or manuscript,
and at least seven (7) days in advance in the case of an abstract. At the
request of VIACELL, Investigators shall delete any of VIACELL's Confidential
Information provided under Appendix C from such presentation, manuscript or
abstract. If, during its review period, VIACELL notifies GENERAL and
Investigators that the proposed disclosure reveals a potentially patentable
invention, Investigators agree to defer submission for publication, or, if
practicable, presentation, for up to thirty (30) additional days, or until a
patent application is filed, whichever occurs first. At the end of such seven,
thirty or maximum sixty day period, as the case may be, Investigators shall be
free to make such presentation or to submit such manuscript or abstract for
publication at their discretion.

         7. Principal Investigator and any other Investigator who shall conceive
and reduce to practice an invention, solely or jointly, in the performance of
the Project (hereinafter referred to as "Invention") shall promptly report such
Invention to GENERAL and shall assign all of his or her rights, title and
interest in the Invention to GENERAL. GENERAL shall promptly advise VIACELL in
writing of each Invention disclosed to GENERAL and shall discuss with VIACELL
whether a patent application or applications (together with any patents issued
thereon, "Patent Rights") pertaining to such Invention should be filed and in
which countries. In the event of joint inventorship between VIACELL personnel
and GENERAL Investigators, VIACELL personnel shall assign all of their rights,
title and interest in the Invention ("Joint Invention") to VIACELL, and GENERAL
Investigators shall assign all of their rights, title and interest in the Joint
Invention to GENERAL, and the Joint Invention will be deemed to be jointly
owned. If both parties mutually agree that Patent Rights should be filed,
applications assigned solely to GENERAL shall be filed by GENERAL, and
applications owned jointly by GENERAL and VIACELL shall be filed as mutually
agreed upon by the parties. In the event VIACELL is not interested in having
Patent Rights filed with respect to a particular Invention, VIACELL shall advise
GENERAL of such fact within ninety (90) days from the date on which the

                                       3
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Invention was disclosed to VIACELL by GENERAL and GENERAL shall be free to file
and prosecute Patent Rights on such Invention (including GENERAL's rights in any
Joint Invention) at its own expense and to license such Patent Rights to any
other party.

         All information given to VIACELL by GENERAL in accordance with this
Paragraph 7 will be held in confidence by VIACELL so long as such information
remains unpublished or publicly undisclosed by GENERAL.

         All patent costs pertaining to any Patent Rights filed by mutual
agreement of VIACELL and GENERAL, including preparation, filing, prosecution,
issuance and maintenance costs, shall be borne by VIACELL.

         As to any Patent Rights assigned in whole or in part to GENERAL and
filed by mutual agreement of the parties, VIACELL shall have (i) a royalty-free,
fully paid-up, non-exclusive, worldwide license under any intellectual property
rights for VIACELL's internal research use, and (ii) for the for the twelve (12)
months next following the filing of such Patent Rights in the United States
Patent and Trademark Office the option to obtain a world-wide, royalty bearing,
exclusive license under the rights assigned by Investigators to GENERAL therein
with the right to sublicense. It is understood that GENERAL will reserve the
right to use any Invention for research, clinical and educational purposes, and
that if federal funding supports the Invention, VIACELL's license will be
subject to the rights, conditions and limitations imposed by U.S. law including
without limitation the royalty-free non-exclusive license granted to the U.S.
government (see 35 USC sec. 202 et seq. and regulations pertaining thereto).

         This option is to be exercised by written notice to GENERAL during said
twelve month period and the negotiation, during the six (6) months next
following such notice, of a license agreement containing license terms standard
for agreements between universities and industry including without limitation
clauses providing for payment of reasonable royalties and other compensation to
GENERAL, objective, time-limited due diligence provisions for the development,
commercialization and marketing of a product embodying the Invention and product
liability indemnification and insurance requirements which are acceptable to
GENERAL's liability insurance carrier. In the absence of such notice by VIACELL
and agreement on license terms, GENERAL may grant a license to such Patent
Rights to any other party.

         8. GENERAL and VIACELL shall each be responsible and shall hold the
other and its directors, trustees, employees, and staff harmless for any injury
to persons or damage to property, to the extent that such injury or damage is
caused by the negligence or the reckless or intentional misconduct of their
directors, trustees, employees or staff in carrying out the Project; provided,
however, that VIACELL will hold harmless GENERAL and its directors, trustees,
employees, and staff against any and all actions, suits, claims, demands or
prosecutions that may be brought or instituted against GENERAL and/or its
directors, trustees, employees and staff

                                       4
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
based on or arising out of the manufacture, use, sale or other distribution of
any product by VIACELL, its affiliates or licensees, or the use of the results
of the research or any material transferred by GENERAL to VIACELL, its
affiliates or licensees, excepting any such action, suit, claim, demand or
prosecution which is based solely on the negligence or reckless or intentional
misconduct of GENERAL and/or its directors, trustees, employees or staff in the
use of such product. Any party entitled to indemnification hereunder shall give
the indemnifying party prompt notice of any covered claim, shall provide the
indemnifying party with the opportunity to defend against the claim, and shall
reasonably cooperate in such defense.

         9. Each party agrees that, except as required by applicable laws or
regulations, it shall not use the name or logo of the other party or of any
employee or staff member of the other party in any advertising, promotional
material, press release or other publicity without the prior written consent of
such party, which consent shall not be unreasonably withheld or delayed.

         10. Any request, notice, report, approval or other communication
required or permitted under this Agreement will be in writing (except in the
case of verbal communications and teleconferences updating either party as to
the status of work hereunder), should be addressed as set forth below or such
other address as either party may designate:

To VIACELL:          ViaCell Inc.
                     One Innovation Drive
                     Worcester, MA 01605
                     Attn:  Seth Finklestein, M.D.
                     cc:  Sharon Pick, Director of Business Development

To GENERAL:          Massachusetts General Hospital
                     Thirteenth Street, Building 149
                     Charlestown, MA 02129
                     Attn:  Director, Corporate Sponsored Research & Licensing

To Investigator:     Robert H. Brown, Jr., D. Phil, M.D.
                     Massachusetts General Hospital
                     Day Lab, MGH-East, Room 3125
                     Building 114, Navy Yard
                     Charlestown, MA 02129

11. If either party shall fail to faithfully perform any of its obligations
under this Agreement, the non-defaulting party may give written notice of the
default to the defaulting party. Unless such default is corrected within thirty
(30) days after such notice, the notifying party may terminate this Agreement
upon written notice. Expiration or termination of this

                                       5
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
Agreement for any reason shall be without prejudice to any rights that shall
have accrued to the benefit of either party prior to such expiration or
termination, and shall not relieve either party of any obligations that have
accrued to either party prior to such expiration or termination or that survive
such expiration or termination (including, without limitation, under Articles 4,
5, 6, 7, 8 and 9 of this Agreement). In addition, following expiration or
termination of this Agreement, at VIACELL's request, GENERAL shall return to
VIACELL or destroy, as instructed by VIACELL, the ViaCell Proprietary Materials
and ViaCell Confidential Information.

         12. Neither party shall assign this Agreement or any rights hereunder
without the prior written consent of the other party, except in the case of a
merger, reorganization, sale of substantially all assets or other "change in
control" transaction. Subject to the foregoing, this Agreement shall be binding
upon and inure to the benefit of the Parties hereto and their respective
successors and assigns.

         13. This Agreement shall be governed by the laws of the Commonwealth of
Massachusetts, regardless of the choice of law rules of any jurisdiction.

IN WITNESS WHEREOF, GENERAL and VIACELL have caused this instrument to be
executed.

VIACELL, INC.                    THE GENERAL HOSPITAL CORPORATION

BY:  /s/ Seth Finklestein        BY:  /s/ Marie Lossky
   -----------------------           ---------------------------------------

NAME   Seth Finklestein          NAME:  Marie Lossky
      -------------------              -------------------------------------

TITLE:   VP, Neuroscience        TITLE:   Industry Agreement Manager
      -------------------              -------------------------------------

DATE:  1/2/01                    DATE:      12/18/01
      ------------------              --------------------------------------

I have read Paragraphs 5, 6 and 7 of the foregoing Agreement and agree to comply
with the obligations of the Principal Investigator/Investigators stated therein.
In addition, I have read Appendix C and agree to comply with the obligations of
GENERAL stated therein.

                                         /s/ Robert Brown
                                      -----------------------------

                                      NAME:  Dr. Robert Brown

                                      DATE:        12/20/01
                                           ------------------------

                                       6
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                   APPENDIX A

         PROPOSAL FOR ADMINISTRATION OF HUMAN UMBILICAL CORD BLOOD CELLS
                        IN AMYOTROPHIC LATERAL SCLEROSIS

                                  submitted by:

                          Robert H. Brown, Jr., M.D.
                          Day Lab, MGH-East, Room 3125
                          Building 114, Navy Yard
                          Charlestown, MA 02129
                          Ph:  617-726-5750
                          Fx:  617-726-8543
                          Em: brown@helix.mgh.harvard.edu

                                       to:

                             Seth Finklestein, M.D.
                                  Viacell, Inc.
                                 DRAFT 10-10-01

                                       1
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>
                                       [*]

        9 pages omitted pursuant to a request for confidential treatment

                                       2
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.
<PAGE>

                                   APPENDIX B

                                      [*]

        4 pages omitted pursuant to a request for confidential treatment

                                       2

* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and
Exchange Commission.
<PAGE>
                                   APPENDIX C

                            CONFIDENTIAL INFORMATION

         It is anticipated that in the performance of the Project, the parties
will be provided with or given access to certain information of the other party
which that party considers proprietary. The rights and obligations of the
parties with respect to such information are as follows:

1. CONFIDENTIAL INFORMATION. For purposes of this Agreement, the term
"Confidential Information" shall mean any confidential or proprietary
scientific, technical, trade or business information given by one party (the
"Disclosing Party") to the other party (the "Receiving Party") in connection
with this Agreement. The Receiving Party shall use the Confidential Information
of the Disclosing Party only in accordance with the activities contemplated by
this Agreement and shall use its reasonable efforts to not disclose to any third
party any Confidential Information of the Disclosing Party, without the prior
written consent of the Disclosing Party. The foregoing obligation shall survive
the expiration or termination of this Agreement for a period of five (5) years.
This obligation shall not apply to Confidential Information that:

         (a) is known by the Receiving Party at the time of its receipt, and not
through a prior disclosure by the Disclosing Party to the Receiving Party, as
documented by business records;
         (b) at the time of disclosure or thereafter becomes published or
otherwise part of the public domain without breach of this Agreement by the
Receiving Party;
         (c) is subsequently disclosed to the Receiving Party by a third party
who has the right to make such disclosure;
         (d) is developed by the Receiving Party independently of proprietary
information or other information received from the Disclosing Party and such
independent development can be properly demonstrated by the Receiving Party; or
         (e) is required to be disclosed by law or court order, provided that
notice is promptly delivered to the Disclosing Party in order to provide an
opportunity to seek a protective order or other similar order with respect to
such proprietary information and thereafter the Receiving Party discloses only
the minimum information required to be disclosed in order to comply with the
request, whether or not a protective order or other similar order is obtained by
the Disclosing Party.

                                       3
* Confidential treatment has been requested with respect to certain portions of
this exhibit. Such portions are marked with a "[*]" in place of the redacted
language. Omitted portions are filed separately with the Securities and Exchange
Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]